Russell Investments Group
MPLT

Russell Investments Group’s MapLight Therapeutics MPLT Stock Holding History

Russell Investments Group’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$260K Buy
7,267
+5,930
+444% +$171K ﹤0.01% 3074
2026
Q1 		$27.2K Hold
1,337
– – ﹤0.01% 3520
2025
Q4 		$23.5K Buy
+1,337
New +$22.4K ﹤0.01% 3575

Other funds holding MPLT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
MSWMA
Market Street Wealth Management Advisors Indianapolis, Indiana $703M AUM 16.2% 1-Year Est. Return
MPW
MA Private Wealth San Carlos, California $671M AUM 23.37% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Russell Investments Group's MPLT Position: Q2 2026 in Review

Russell Investments Group increased its MapLight Therapeutics (MPLT) stake by 444% in Q2 2026, buying an estimated $171K and bringing the position to 7,267 shares worth $260K. The position accounts for ﹤0.01% of the portfolio, ranked #3074.

Russell Investments Group first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. 25 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Russell Investments Group held 7,267 shares of MapLight Therapeutics worth $260K as of Q2 2026.
  • Russell Investments Group bought 5,930 MapLight Therapeutics shares in Q2 2026, an estimated $171K.
  • MapLight Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3074 holding.
  • Russell Investments Group first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 25 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.